Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Prothena (PRTA) reported a wider loss per share due to higher expenses and lower revenues. - Total revenues in Q1 were $0.05 million, missing estimates and declining from the previous year. - Pipeline updates include ongoing studies for Alzheimer's and Parkinson's disease treatments. - Share price of PRTA has fallen 36.6% year to date compared to the industry. Price Impact Rating: Bearish Impact Horizon Rating: Long-term Type: Research Analysis
- Prothena (PRTA) reported a wider loss per share due to higher expenses and lower revenues.
- Total revenues in Q1 were $0.05 million, missing estimates and declining from the previous year.
- Pipeline updates include ongoing studies for Alzheimer's and Parkinson's disease treatments.
- Share price of PRTA has fallen 36.6% year to date compared to the industry.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.